WO2003084565A3 - Ve-ptp as regulator of ve-cadherin mediated processes or disorders - Google Patents

Ve-ptp as regulator of ve-cadherin mediated processes or disorders Download PDF

Info

Publication number
WO2003084565A3
WO2003084565A3 PCT/EP2003/003645 EP0303645W WO03084565A3 WO 2003084565 A3 WO2003084565 A3 WO 2003084565A3 EP 0303645 W EP0303645 W EP 0303645W WO 03084565 A3 WO03084565 A3 WO 03084565A3
Authority
WO
WIPO (PCT)
Prior art keywords
ptp
disorders
regulator
mediated processes
cadherin mediated
Prior art date
Application number
PCT/EP2003/003645
Other languages
French (fr)
Other versions
WO2003084565A2 (en
Inventor
Roman Nawroth
Urban Deutsch
Dietmar Vestweber
David T Shima
Matthew Golding
Original Assignee
Max Planck Gesellschaft
Roman Nawroth
Urban Deutsch
Dietmar Vestweber
David T Shima
Matthew Golding
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft, Roman Nawroth, Urban Deutsch, Dietmar Vestweber, David T Shima, Matthew Golding filed Critical Max Planck Gesellschaft
Priority to AU2003229627A priority Critical patent/AU2003229627A1/en
Publication of WO2003084565A2 publication Critical patent/WO2003084565A2/en
Publication of WO2003084565A3 publication Critical patent/WO2003084565A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to the use of vascular endothelial-protein tyrosine phosphatase (VE-PTP), a nucleic acid molecule coding therefor or an effector of the polypeptide or the nucleic acid molecule for the manufacture of an agent for monitoring or modulating VE-cadherin mediated processes or disorders.
PCT/EP2003/003645 2002-04-08 2003-04-08 Ve-ptp as regulator of ve-cadherin mediated processes or disorders WO2003084565A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003229627A AU2003229627A1 (en) 2002-04-08 2003-04-08 Ve-ptp as regulator of ve-cadherin mediated processes or disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02007837 2002-04-08
EP02007837.4 2002-04-08

Publications (2)

Publication Number Publication Date
WO2003084565A2 WO2003084565A2 (en) 2003-10-16
WO2003084565A3 true WO2003084565A3 (en) 2004-03-25

Family

ID=28685843

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/003645 WO2003084565A2 (en) 2002-04-08 2003-04-08 Ve-ptp as regulator of ve-cadherin mediated processes or disorders

Country Status (2)

Country Link
AU (1) AU2003229627A1 (en)
WO (1) WO2003084565A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006055416A2 (en) * 2004-11-15 2006-05-26 Eyetech Pharmaceuticals, Inc. Transgenic mouse capable of over-expressing vascular endothelial protein tyrosine phosphatase (ve-ptp)
KR20110122881A (en) 2006-04-07 2011-11-11 워너 칠콧 컴퍼니 엘엘씨 Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
JP5536113B2 (en) 2009-07-06 2014-07-02 アケビア セラピューティクス インコーポレイテッド Compounds, compositions and methods for preventing metastasis of cancer cells
AU2012323856B2 (en) 2011-10-13 2017-05-25 EyePoint Pharmaceuticals, Inc. Methods for treating Vascular Leak Syndrome and cancer
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
JP6483148B2 (en) 2014-03-14 2019-03-13 エアーピオ セラピューティクス インコーポレイテッド HPTP-β inhibitor
WO2016115092A1 (en) * 2015-01-12 2016-07-21 La Jolla Institute For Allergy And Immunology Methods for targeting host vascular mechanism for therapeutic protection against hemorrhagic fever
CN108290057A (en) 2015-09-23 2018-07-17 爱尔皮奥治疗有限公司 With the method for the activators for treating intraocular pressure of TIE-2
JP2022530657A (en) 2019-04-29 2022-06-30 アイポイント ファーマシューティカルズ， インコーポレイテッド Tie-2 activator targeting Schlemm's canal

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998025946A1 (en) * 1996-12-12 1998-06-18 Imclone Systems Incorporated Monoclonal antibodies specific to endothelial cell cadherins and uses thereof
EP1046715A1 (en) * 1999-04-23 2000-10-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Interaction of vascular-endothelial protein-tyrosine phosphatase with the angiopoietin receptor tie-2

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998025946A1 (en) * 1996-12-12 1998-06-18 Imclone Systems Incorporated Monoclonal antibodies specific to endothelial cell cadherins and uses thereof
EP1046715A1 (en) * 1999-04-23 2000-10-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Interaction of vascular-endothelial protein-tyrosine phosphatase with the angiopoietin receptor tie-2

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
R. NAWROTH ET AL.: "VE-PTP and VE-cadherin ectodomains interact to facilitate regulation of phosphorylation and cell contacts.", THE EMBO JOURNAL., vol. 21, no. 18, 16 September 2002 (2002-09-16), EYNSHAM, OXFORD, GB, pages 4885 - 4895, XP002254050 *
U. GOTSCH ET AL.: "VE-cadherin antibody accelerates neutrophil recruitment in vivo.", JOURNAL OF CELL SCIENCE, vol. 110, 1997, pages 583 - 588, XP002254049 *

Also Published As

Publication number Publication date
AU2003229627A1 (en) 2003-10-20
WO2003084565A2 (en) 2003-10-16

Similar Documents

Publication Publication Date Title
EP1308459A3 (en) Full-length cDNA sequences
EP1440981A3 (en) Full-length human cdna
WO2003012105A3 (en) Vegf isoform
WO2003025148A3 (en) Novel nucleic acids and polypeptides
WO2003023013A3 (en) Novel nucleic acids and polypeptides
WO2002081731A3 (en) Novel nucleic acids and polypeptides
MX2009007001A (en) Phenazine and quinoxaline substituted amino acids and polypeptides.
WO2004080148A3 (en) Novel nucleic acids and polypeptides
WO2000018899A3 (en) Angiotensin converting enzyme homolog and its use
WO2003084565A3 (en) Ve-ptp as regulator of ve-cadherin mediated processes or disorders
PT1390525E (en) Pyruvate-kinase as a novel target molecule
WO2004007664A3 (en) Nucleic acid vectors
MXPA05010277A (en) Nail polish composition and method of making same.
WO2002063005A3 (en) Lipid-associated molecules
WO2004006862A3 (en) A method for the modulation of angiogenesis
CA2527630A1 (en) Aqueous compositions based on polychloroprene
WO2005049644A3 (en) Tool for the transfer and production of proteins using the pseudomonas type iii secretion system
WO2003089569A3 (en) Use of il-19, il-22 and il-24 to treat hematopoietic disorders
WO2003094848A3 (en) Nucleic acid-associated proteins
WO2004076614A3 (en) Human nucleic acid sequences obtained from prostatic carcinomas
WO2002012471A3 (en) Angiotensin converting enzyme homolog and uses therefor
WO2004044165A3 (en) Lipid-associated proteins
WO2003068943A3 (en) Secreted proteins
PL374550A1 (en) Il-17 like molecules and uses thereof
WO2005017174A3 (en) Process for the purification of recombinant polypeptides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP